Open access
Open access
Powered by Google Translator Translator

Oncology – Breast

Phase II RCT: Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic estrogen receptor-positive, HER2-negative breast cancer.

22 Jun, 2022 | 10:49h | UTC

Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)

Commentary: Switch to Maintenance Endocrine Therapy Plus Bevacizumab After First-Line Paclitaxel/Bevacizumab Induction in Advanced Estrogen Receptor–Positive, HER2-Negative Breast Cancer – The ASCO Post

 


NCCN Updated Guideline: Breast cancer.

20 Jun, 2022 | 01:24h | UTC

Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology – Journal of the National Comprehensive Cancer Network

 


Cohort Study: Association of screening with digital breast tomosynthesis vs. digital mammography with risk of interval invasive and advanced breast cancer.

17 Jun, 2022 | 11:09h | UTC

Association of Screening With Digital Breast Tomosynthesis vs Digital Mammography With Risk of Interval Invasive and Advanced Breast Cancer – JAMA (free for a limited period)

Editorial: Digital Breast Tomosynthesis and Detection of Interval Invasive and Advanced Breast Cancers – JAMA (free for a limited period)

News Release: 3-D Mammography Technique Benefits Some Women, Not All – University of California San Francisco

 


Regional lymphadenopathy following COVID-19 vaccination in patients with or suspicious of breast cancer: a quick summary of current key facts and recommendations.

14 Jun, 2022 | 11:07h | UTC

Regional Lymphadenopathy Following COVID-19 Vaccination in Patients with or Suspicious of Breast Cancer: A Quick Summary of Current Key Facts and Recommendations – Korean Journal of Radiology

Related:

2 Case Series and Guidance | Lymphadenopathy in COVID-19 Vaccine Recipients

Axillary lymphadenopathy at the time of COVID-19 vaccination: ten recommendations from the European Society of Breast Imaging (EUSOBI) – Insights into Imaging

Covid-19: Schedule breast screening before vaccine or 4 to 6 weeks after to avoid false positives, says guidance – The BMJ

Frequency and outcomes of MRI-detected axillary adenopathy following COVID-19 vaccination – European Radiology

Regional lymphadenopathy following COVID-19 vaccination: Literature review and considerations for patient management in breast cancer care – European Journal of Cancer

 


Circulating tumor DNA and late recurrence in high-risk hormone receptor–positive, human epidermal growth factor receptor 2–negative breast cancer.

13 Jun, 2022 | 07:35h | UTC

Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer – Journal of Clinical Oncology

Editorial: Can a Late Interception by Circulating Tumor DNA Deliver a Win in Estrogen Receptor–Positive Early Breast Cancer?

Commentary: Tumor DNA Assay Portends Metastatic Breast Cancer Recurrence Months in Advance — First evidence for patients in late adjuvant setting, years after initial diagnosis – MedPage Today (free registration required)

 

Commentary on Twitter

 


Cohort Study: Long-term quality of life in patients with breast cancer after breast conservation vs mastectomy and reconstruction.

9 Jun, 2022 | 10:30h | UTC

Long-term Quality of Life in Patients With Breast Cancer After Breast Conservation vs Mastectomy and Reconstruction – JAMA Surgery (link to abstract – $ for full-text)

Commentaries:

Long-Term QOL Examined for Surgical Choices in Breast Cancer – HealthDay

Improved Long-Term Quality-of-Life Measures in Women Undergoing Breast Conservation vs Mastectomy and Reconstruction for Early Breast Cancer – The ASCO Post

 

Commentary on Twitter

 


#ASCO22 – RCT: Trastuzumab Deruxtecan in previously treated HER2-low advanced breast cancer.

6 Jun, 2022 | 11:18h | UTC

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Trastuzumab Deruxtecan Cuts Risk of Disease Progression or Death by 50% for Patients With HER2-Low Metastatic Breast Cancer – AJMC

 

Commentary on Twitter

 


Phase 2 RCT: Efficacy of epigallocatechin-3-gallate in preventing dermatitis in patients with breast cancer receiving postoperative radiotherapy.

2 Jun, 2022 | 10:34h | UTC

Efficacy of Epigallocatechin-3-Gallate in Preventing Dermatitis in Patients With Breast Cancer Receiving Postoperative Radiotherapy: A Double-Blind, Placebo-Controlled, Phase 2 Randomized Clinical Trial – JAMA Dermatology (free for a limited period)

Visual Abstract: Efficacy of Epigallocatechin-3-Gallate on Dermatitis in Patients With Breast Cancer Receiving Postoperative Radiotherapy

 


Expert Analysis: Cardiotoxicity and the evolving landscape of HER2-targeted breast cancer treatment.

2 Jun, 2022 | 10:11h | UTC

Cardiotoxicity and the Evolving Landscape of HER2-Targeted Breast Cancer Treatment – American College of Cardiology

 


ASCO Guideline Update: Systemic therapy for advanced human epidermal growth factor receptor 2–positive breast cancer.

1 Jun, 2022 | 11:38h | UTC

Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Guideline Update – Journal of Clinical Oncology

 

Commentary on Twitter

 


ASCO Guideline Update: Management of advanced human epidermal growth factor receptor 2–positive breast cancer and brain metastases.

1 Jun, 2022 | 11:36h | UTC

Management of Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: ASCO Guideline Update – Journal of Clinical Oncology

 

Commentary on Twitter

 


Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.

31 May, 2022 | 10:46h | UTC

Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies – Cancer Cell

 

Commentary on Twitter

 


RCT: Effect of supine vs. prone breast radiotherapy on acute toxic effects of the skin among women with large breast size.

27 May, 2022 | 11:51h | UTC

Effect of Supine vs Prone Breast Radiotherapy on Acute Toxic Effects of the Skin Among Women With Large Breast Size: A Randomized Clinical Trial – JAMA Oncology (free for a limited period)

Editorial: Prone Whole-Breast Radiotherapy—Better Than Supine? (free for a limited period)

 

Commentary on Twitter

 


Position Paper: Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer.

26 May, 2022 | 10:42h | UTC

Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies – ESMO Open

 


RCT: The addition of Metformin to standard therapy did not improve outcomes in patients with breast cancer.

25 May, 2022 | 11:49h | UTC

Effect of Metformin vs Placebo on Invasive Disease–Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial – JAMA (free for a limited period)

Editorial: Who Will Benefit From Metformin? – JAMA Oncology

News Release: Common diabetes drug not effective against early-stage breast cancer, landmark trial reveals – Lunenfeld-Tanenbaum Research Institute

 


RCT: Everolimus is not beneficial when added to adjuvant endocrine therapy in patients with high-risk hormone receptor–positive, human epidermal growth factor receptor 2–negative primary breast cancer.

25 May, 2022 | 10:57h | UTC

Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Primary Breast Cancer – Journal of Clinical Oncology

 

Commentaries on Twitter

 


RCT: Effect of Denosumab added to 2 different nab-paclitaxel regimens as neoadjuvant therapy in patients with primary breast cancer.

25 May, 2022 | 10:54h | UTC

Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)

 

Commentary on Twitter

 


RCT: Elacestrant (oral selective estrogen receptor degrader) vs. standard endocrine therapy for estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer.

20 May, 2022 | 10:55h | UTC

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial – Journal of Clinical Oncology

Commentary: EMERALD Trial: Oral Selective Estrogen Receptor Degrader as Second- or Third-Line Therapy for Advanced Breast Cancer – The ASCO Post

 


Mammographic breast density, benign breast disease, and subsequent breast cancer risk in 3.9 million Korean women.

19 May, 2022 | 10:51h | UTC

Mammographic Breast Density, Benign Breast Disease, and Subsequent Breast Cancer Risk in 3.9 Million Korean Women – Radiology

News Release: Density, benign disease raise risk of breast cancer – Radiological Society of North America

 


Hair safe study: Effects of scalp cooling on hair preservation and hair regrowth in breast cancer patients receiving chemotherapy – A prospective interventional study.

19 May, 2022 | 10:15h | UTC

Hair safe study: Effects of scalp cooling on hair preservation and hair regrowth in breast cancer patients receiving chemotherapy – A prospective interventional study – The Breast

 


Nonrandomized Controlled Trial: Clinical impact of intraoperative margin assessment in breast-conserving surgery with a novel Pegulicianine Fluorescence–guided system.

18 May, 2022 | 10:28h | UTC

Clinical Impact of Intraoperative Margin Assessment in Breast-Conserving Surgery With a Novel Pegulicianine Fluorescence–Guided System: A Nonrandomized Controlled Trial – JAMA Surgery

 

Commentary on Twitter

 


M-A: Electronic health interventions for patients with breast cancer.

16 May, 2022 | 01:16h | UTC

Electronic Health Interventions for Patients With Breast Cancer: Systematic Review and Meta-Analyses – Journal of Clinical Oncology

 


RCT: Treatment with Etirinotecan pegol for patients with metastatic breast cancer and brain metastases.

13 May, 2022 | 10:51h | UTC

Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial – JAMA Oncology (free for a limited period)

 

Commentary on Twitter

 


Retrospective Cohort Study: Identification of patients with branch-duct intraductal papillary mucinous neoplasm and very low risk of cancer.

9 May, 2022 | 01:40h | UTC

Identification of patients with branch-duct intraductal papillary mucinous neoplasm and very low risk of cancer: multicentre study – British Journal of Cancer

 

Commentary on Twitter

 


A Canadian national guideline on the neoadjuvant treatment of invasive breast cancer, including patient assessment, systemic therapy, and local management principles.

6 May, 2022 | 10:52h | UTC

A Canadian national guideline on the neoadjuvant treatment of invasive breast cancer, including patient assessment, systemic therapy, and local management principles – Breast Cancer Research and Treatment

 


Stay Updated in Your Specialty

No spam, just news.